What we are studying
The purpose of this study is to compare the effects, good or bad, of Rituximab with another drug called mycophenolate mofetil (MMF) in treating patients with pemphigus vulgaris. Both drugs have been available worldwide for over 15 years to treat other diseases; however, none of them have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of pemphigus vulgaris.
$1,360. $50 per visit and $190 per visit on infusion days.